A m 6 A methyltransferase-mediated immune signature determines prognosis, immune landscape and immunotherapy efficacy in patients with lung adenocarcinoma.
Mengyuan LeiChenghan LuoJiayang ZhangWenjun CaoJian GeMin ZhaoPublished in: Cellular oncology (Dordrecht) (2022)
A-mediated immune model may be useful to predict the immunotherapy responses and outcomes of patients with LUAD.